SOURCE: Kalexsyn, Inc.

March 23, 2011 11:00 ET

KALEXSYN and BioRelix Announce Extension of Collaboration to Identify Anti-Bacterial Drug Candidates

KALAMAZOO, MI and NEW HAVEN, CT--(Marketwire - March 23, 2011) - KALEXSYN, Inc. a drug discovery and development company, and BioRelix, Inc., the leader in discovery and development of riboswitch-based therapeutics, announced today that they have entered into an agreement in which KALEXSYN will provide medicinal chemistry services to drive BioRelix's ongoing research activities directed at the discovery of new anti-bacterial drugs. The terms of the agreement were not disclosed.

BioRelix is discovering and developing new treatments for infectious diseases that target riboswitches -- an innovative class of RNA drug targets found in pathogenic bacteria and fungi. "KALEXSYN has been a key collaborator on medicinal chemistry strategy and has provided high impact synthetic expertise to BioRelix for several years. We have a history of success with BioRelix and we are pleased to continue our collaboration with their research team," commented David Zimmermann, KALEXSYN chief executive officer.

Brian Dixon, Ph.D., chief executive officer of BioRelix, noted, "KALEXSYN is a premier provider of medicinal chemistry. We chose to work with KALEXSYN because of their expertise and their ability to fully engage in the scientific discovery process with our research team."

KALEXSYN is a world-class medicinal chemistry CRO. Our scientists average 15 years of experience in IP-enabling medicinal chemistry, structure activity relationship design, custom synthesis, stable label synthesis, early API scale-up and process improvement chemistry. We offer clients an outstanding CRO experience with tailored short and long term contract arrangements. Founded in 2003, KALEXSYN is located in Kalamazoo, Michigan and privately owned. For more information about the company, please visit

About BioRelix
BioRelix, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed riboswitches, which were identified by the laboratory of BioRelix co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, Novartis Venture Funds, Aisling Capital, New Leaf Venture Partners, Elm Street Ventures and Alexandria Real Estate Equities, Inc.

Contact Information

  • Contact
    David Zimmermann
    KALEXSYN, Inc.
    (269) 760-0403
    Email Contact